{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:29:35Z","timestamp":1789014575963,"version":"build-2803163510"},"reference-count":77,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,12,23]],"date-time":"2015-12-23T00:00:00Z","timestamp":1450828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2016,1]]},"abstract":"<jats:p>The efficacy of second\u2010line treatment for chronic myeloid leukemia (CML) plays an important role in allowing CML patients to enjoy a normal life expectancy. Four tyrosine kinase inhibitors (TKIs) are presently available: bosutinib, dasatinib, nilotinib, ponatinib. Each one has different safety and activity profiles, which are reviewed here. No controlled studies are available to guide treatment decision, which must be based on the characterization of leukemic cells, especially in cases of resistance to TKI, coupled with the safety profile of each TKI. Patient comorbidities also play an important role in the treatment decision, which can achieve a new durable response in over 50% of treated patients. Am. J. Hematol. 91:67\u201375, 2016. \u00a9 2015 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.24247","type":"journal-article","created":{"date-parts":[[2015,11,20]],"date-time":"2015-11-20T16:10:25Z","timestamp":1448035825000},"page":"67-75","source":"Crossref","is-referenced-by-count":34,"title":["Chronic myeloid leukemia: Second\u2010line drugs of choice"],"prefix":"10.1002","volume":"91","author":[{"given":"Carlo","family":"Gambacorti\u2010Passerini","sequence":"first","affiliation":[{"name":"Department of Medicine and Surgery University of Milano\u2010Bicocca, Section of Hematology, San Gerardo Hospital Monza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Aroldi","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery University of Milano\u2010Bicocca, Section of Hematology, San Gerardo Hospital Monza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Cordani","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery University of Milano\u2010Bicocca, Section of Hematology, San Gerardo Hospital Monza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Piazza","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery University of Milano\u2010Bicocca, Section of Hematology, San Gerardo Hospital Monza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,12,23]]},"reference":[{"key":"e_1_2_17_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/315758a0"},{"key":"e_1_2_17_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(84)90438-0"},{"key":"e_1_2_17_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0596-561"},{"key":"e_1_2_17_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.9.3691"},{"key":"e_1_2_17_6_1","doi-asserted-by":"publisher","DOI":"10.1006\/bcmd.1997.0155"},{"key":"e_1_2_17_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23804"},{"key":"e_1_2_17_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.36"},{"key":"e_1_2_17_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr060"},{"key":"e_1_2_17_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2013.11.002"},{"key":"e_1_2_17_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.38"},{"key":"e_1_2_17_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.9020"},{"key":"e_1_2_17_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23887"},{"key":"e_1_2_17_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403928"},{"key":"e_1_2_17_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055229"},{"key":"e_1_2_17_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055104"},{"key":"e_1_2_17_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306494"},{"key":"e_1_2_17_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-355594"},{"key":"e_1_2_17_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"e_1_2_17_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23728"},{"key":"e_1_2_17_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_17_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-566323"},{"key":"e_1_2_17_23_1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2011.0125","article-title":"NCCN Task Force report: Tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia","volume":"9","author":"O'Brien S","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"key":"e_1_2_17_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(03)00979-3"},{"key":"e_1_2_17_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23338"},{"key":"e_1_2_17_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-326405"},{"key":"e_1_2_17_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-154344"},{"key":"e_1_2_17_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-197715"},{"key":"e_1_2_17_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-196543"},{"key":"e_1_2_17_30_1","article-title":"Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia","author":"Moslehi JJ","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015"},{"key":"e_1_2_17_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1266"},{"key":"e_1_2_17_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23938"},{"key":"e_1_2_17_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_2_17_34_1","unstructured":"Bristol Myers Squibb. Dasatinib Prescribing Information.2015."},{"key":"e_1_2_17_35_1","unstructured":"Novartis Pharmaceuticals Corporation. Nilotinib Prescribing Information. East Hanover NJ2015."},{"key":"e_1_2_17_36_1","unstructured":"Pfizer Inc. Bosutinib Prescribing Information. November 2014.2014."},{"key":"e_1_2_17_37_1","unstructured":"ARIAD Pharmaceuticals Inc. Ponatinib Prescribing Information.2014."},{"key":"e_1_2_17_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.215"},{"key":"e_1_2_17_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-513937"},{"key":"e_1_2_17_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-1199"},{"key":"e_1_2_17_41_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11680"},{"key":"e_1_2_17_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.04.217"},{"key":"e_1_2_17_43_1","first-page":"122","article-title":"Prospective analysis of plasma cholesterol and triglycerides in patients (pts) with chronic phase (CP)-chronic myeloid leukemia (CML) during treatment with the 2nd generation tyrosine kinase inhibitor (TKI) nilotinib","author":"Rea D","year":"2013","journal-title":"Blood"},{"key":"e_1_2_17_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.09.016"},{"key":"e_1_2_17_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-104281"},{"key":"e_1_2_17_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.02.005"},{"key":"e_1_2_17_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.08.003"},{"key":"e_1_2_17_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.988"},{"key":"e_1_2_17_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.85"},{"key":"e_1_2_17_50_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2010.0251"},{"key":"e_1_2_17_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13554-4"},{"key":"e_1_2_17_52_1","first-page":"291","article-title":"Tyrosine kinase inhibitors and acute pancreatitis","volume":"11","author":"Pezzilli R","year":"2010","journal-title":"Jop"},{"key":"e_1_2_17_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23788"},{"key":"e_1_2_17_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26062"},{"key":"e_1_2_17_55_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S80207"},{"key":"e_1_2_17_56_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.9260"},{"key":"e_1_2_17_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-532341"},{"key":"e_1_2_17_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-11-186817"},{"key":"e_1_2_17_59_1","first-page":"1395","article-title":"Severe adverse events associated with the use of second\u2010line BCR\/ABL tyrosine kinase inhibitors: Preferential occurrence in patients with comorbidities","volume":"96","author":"Valent P.","year":"2011","journal-title":"Haematologica"},{"key":"e_1_2_17_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2020"},{"key":"e_1_2_17_61_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.079921"},{"key":"e_1_2_17_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24257"},{"key":"e_1_2_17_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22037"},{"key":"e_1_2_17_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22084"},{"key":"e_1_2_17_65_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5580"},{"key":"e_1_2_17_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-594432"},{"key":"e_1_2_17_67_1","first-page":"32","article-title":"ENESTnd 5\u2010year (y) update: Long\u2010term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML\u2010CP) treated with frontline nilotinib (NIL) versus imatinib (IM)","author":"Larson RA","year":"2014","journal-title":"J Clin Oncol"},{"key":"e_1_2_17_68_1","first-page":"451","article-title":"Bosutinib: A novel src\/abl kinase inhibitor for chronic myelogenous leukemia","volume":"4","author":"Steinbach A","year":"2013","journal-title":"J Adv Pract Oncol"},{"key":"e_1_2_17_69_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp140221"},{"key":"e_1_2_17_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-390120"},{"key":"e_1_2_17_71_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.882898"},{"key":"e_1_2_17_72_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.7522"},{"key":"e_1_2_17_73_1","first-page":"P900","article-title":"Long\u2010term evaluation of vascular toxicity in patients with Ph+ leukemias treated with bosutinib","author":"Cortes J","year":"2014","journal-title":"EHA Meeting, Milano"},{"key":"e_1_2_17_74_1","first-page":"P1105","article-title":"Long\u2010term bosutinib for philadelphia chromosome\u2013positive (Ph+) advanced chronic myeloid leukemia (cml) after prior tyrosine kinase inhibitor failure","author":"Gambacorti\u2010Passerini C","year":"2014","journal-title":"EHA Meeting, Milano"},{"key":"e_1_2_17_75_1","first-page":"99","article-title":"Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia","volume":"6","author":"Amsberg GK","year":"2013","journal-title":"Onco Targets Ther"},{"key":"e_1_2_17_76_1","first-page":"502","article-title":"Sequencing treatment in chronic myeloid leukemia: The first choice may be the hardest","volume":"12","author":"Heaney ML.","year":"2014","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_2_17_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.03.006"},{"key":"e_1_2_17_78_1","unstructured":"Novartis Pharmaceuticals Corporation. Gleevac Prescribing Information. East Hanover NJ2013."}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24247","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24247","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:08:58Z","timestamp":1694477338000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,23]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["10.1002\/ajh.24247"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24247","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,23]]}}}